FTC Sues to Stop Amgen's Multibillion-Dollar Acquisition of Horizon Therapeutics

The Federal Trade Commission filed a lawsuit to block Amgen's $27.8 billion acquisition of Horizon Therapeutics.
The FTC argues the deal would allow Amgen to pressure insurers and benefit managers to favor Horizon's leading drugs.
Amgen says the companies treat different diseases and patient groups, with little overlap.
The FTC's move follows its tougher stance on pharmaceutical deals under Chair Lina Khan.
If blocked, the deal would be a blow to Amgen's strategy to bolster its drug portfolio as patents expire.